Eisai
ESALYNext catalyst
Lenvatinib
Hepatocellular Carcinoma
Get an email about ESALY's next catalysts
Track Eisai (ESALY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 9 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
10 upcoming, 0 past
Lenvatinib Phase 2 Est. Readout
Estimated primary completion for Lenvatinib trial (NCT06138769) in Hepatocellular Carcinoma. Topline data typically follows completion by weeks to months.
SourceLecanemab Phase 2 Est. Readout
Estimated primary completion for Lecanemab trial (NCT06602258) in Alzheimer's Disease. Topline data typically follows completion by weeks to months.
SourceLenvatinib Phase 2 Est. Readout
Estimated primary completion for Lenvatinib trial (NCT04209660) in Adenoid Cystic Carcinoma. Topline data typically follows completion by weeks to months.
SourceLenvatinib + Letrozole Phase 2 Est. Readout
Estimated primary completion for Lenvatinib + Letrozole trial (NCT02562118) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourceE2086 Phase 2 Est. Readout
Primary completion for E2086 trial (NCT07493265) in Narcolepsy
SourceE7389-LF Phase 2 Est. Readout
Estimated primary completion for E7389-LF trial (NCT04078295) in Solid Neoplasms. Topline data typically follows completion by weeks to months.
SourceLenvatinib Phase 2 Est. Readout
Estimated primary completion for Lenvatinib trial (NCT04008797) in Endometrial Neoplasms. Topline data typically follows completion by weeks to months.
SourcePerampanel Oral Suspension Phase 2 Est. Readout
Primary completion for Perampanel Oral Suspension trial (NCT04015141) in Pediatric Epileptic Syndrome
SourceMarket Overview
Stock performance and key metrics
Eszopiclone
Primary Insomnia
avatrombopag (lower baseline platelet count)
Thrombocytopenia Associated With Liver Disease
Lorcaserin
Obesity
AQUAVAN® (fospropofol disodium) Injection
Bronchoscopy
Lenvatinib
Hepatocellular Carcinoma
E2007
Refractory Partial Seizures
Amolimogene
Uterine Cervical Dysplasia
E7337
Lesions of the Liver
Rabeprazole sodium
Gastroesophageal Reflux Disease (GERD)
lemborexant
Insomnia Disorder
Perampanel
Epilepsy
E2007 (perampanel)
Refractory Partial Seizures
fospropofol disodium
Colonoscopy
Rufinamide
Lennox-Gastaut Syndrome
Lecanemab
Preclinical Alzheimer's Disease
E7389
Breast Cancer
E2020
Alzheimer's Type Dementia
LEM
Insomnia
Eribulin
Non-Small Cell Lung Cancer (NSCLC)
Rufinamide (E2080)
Lennox-Gastaut Syndrome
Ranirestat
Mild to Moderate Diabetic Sensorimotor Polyneuropathy
eritoran tetrasodium
Severe Sepsis
E2814
Alzheimer Disease
Avatrombopag
Chronic Thrombocytopenia
Eribulin mesylate intravenous
Soft Tissue Sarcoma
Cinitapride
Dyspepsia
Eperisone
Muscle Spasm; Back Pain
Rabeprazole
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
bexarotene with carboplatin and paclitaxel
Non-small Cell Lung Cancer
E0302 (mecobalamin)
Amyotrophic Lateral Sclerosis (ALS)
Midazolam HCI
Conscious Sedation
Aricept (donepezil IR)
Alzheimer's Disease
Prior Donzepezil
Parkinson's Disease
Zolpidem tartrate
Insomnia
Rabeprazole ER
Gastroesophageal Reflux Disease (GERD)
Sibutramine Hydrochloride Monohydrate
Obesity
E3810
Non-erosive Gastroesophageal Reflux Disease
Lamotrigine
Epilepsy
Carbamazepine
Epilepsy
bexarotene
Non-small Cell Lung Cancer
Midazolam HCl
Colonoscopy
avatrombopag (higher baseline platelet count)
Thrombocytopenia Associated With Liver Disease
Cytarabine or Supportive Care
Acute Myeloid Leukemia
Irofulven
Prostate Cancer
Aricept
Cognitive Impairment
Eribulin Mesylate
Breast Cancer
Belzutifan
Carcinoma, Renal Cell
Gantenerumab
Alzheimers Disease
phylloquinone (K1)
Osteoporosis
Doxorubicin
Breast Cancer
Aricept (donepezil SR)
Alzheimer's Disease
Oxaliplatin
Liver Cancer
everolimus
Renal Cell Carcinoma
Carboplatin
Endometrial Neoplasms
Sorafenib
Hepatocellular Carcinoma (HCC)
Docetaxel
Squamous Cell Carcinoma of Head and Neck
Decitabine
Acute Myeloid Leukemia
Donepezil hydrochloride
Attention Impairment
Open-labelAdalimumabRescue
Rheumatoid Arthritis
alfacalcidol
Postmenopausal Osteoporosis
Any other approved Antiepileptic Drug
Lennox-Gastaut Syndrome
Open-label Adalimumab
Rheumatoid Arthritis
Eszopiclone - Non-elderly
Insomnia
Zonegran
Binge Eating Disorder Associated With Obesity
Donepezil
Alzheimer's Disease
Ranitidine
Gastroesophageal Reflux Disease (GERD)
Donepezil HCl
Down Syndrome
Prior Donepezil
Parkinson's Disease
Pembrolizumab/Quavonlimab
Carcinoma, Renal Cell
Leucovorin (or Levoleucovorin)
Advanced/Metastatic Gastroesophageal Adenocarcinoma
menatetranone (MK4)
Osteoporosis
H. pylori treatment
Iron Deficiency Anemia
Teprenone
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
T-614
Rheumatoid Arthritis
Eszopiclone - Elderly
Insomnia
Eperisone hydrochloride and Diclofenac sodium
Acute Musculoskeletal Spasm Due to Low Back Pain
Clevudine
Chronic Hepatitis B
E7777
Peripheral T-cell Lymphoma
methylcobalamin
Amyotrophic Lateral Sclerosis
E7389 (Eribulin Mesylate)
HER2-Negative Breast Cancer
menatetranone
Postmenopausal Osteoporosis
Dotinurad
Gout
Zonisamide
Epilepsy; Paediatric Partial Onset Seizures
E7389-LF
Solid Neoplasms
Valproic acid
Leukemia
Eribulin mesylate (eribulin; E7389)
Non Small Cell Lung Cancer
Estrogen
Alzheimer Disease
E7080 capsule
Thyroid Cancer
Perampanel Tablet
Pediatric Epileptic Syndrome
Palonosetron (PALO)
Malignant Glioma
Avatrombopag tablets
Chronic Idiopathic Thrombocytopenic Purpura
BOTULINUM TOXIN TYPE B
Cervical Dystonia
Idarubicin
Leukemia
E7090
Cholangiocarcinoma
AQUAVAN (fospropofol disodium; GPI 15715)
Postoperative Sedation
Decitabine, Arsenic Trioxide and Ascorbic Acid
Myelodysplastic Syndrome
Tazemetostat
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
E5564
Sepsis
E6742
Lupus Erythematosus, Systemic
E7050
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
E2014 (Botulinum toxin type B)
Spasmodic Torticollis
Irsenontrine
Dementia With Lewy Bodies
Calcipotriene
Psoriasis Vulgaris
Lenvatinib Pill
Hepatocellular Carcinoma
E5555
Coronary Artery Disease
Farletuzumab
Platinum-Sensitive Ovarian Cancer in First Relapse
fospropofol
Ischemic Coronary Artery Disease
E6201
Chronic Plaque Psoriasis
Irofulven + capecitabine
Thyroid Cancer
BB-1701
Breast Cancer
E7389 28 Day Cycle
Non-Small-Cell Lung Carcinoma
Perampanel Oral Suspension
Pediatric Epileptic Syndrome
E7449 alone
Malignant Solid Tumour
APD356
Obesity
ONTAK (denileukin diftitox)
Lymphoma, B-Cell
Pegylated interferon (PEG-IFN)
Thrombocytopenia
Iomeprole
Lesion
CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
Peripheral T-Cell Lymphoma
E2020-Donepezil hydrochloride
Down Syndrome
Eribulin mesilate
Refractory or Recurrent Solid Tumors
E7070
Kidney Neoplasms
Ixabepilone
Breast Cancer
MORAb-004 (monoclonal antibody)
Metastatic Melanoma
Lenvatinib (DTC Cohort)
Thyroid Cancer
Blinded (Avatrombopoag tablets)
Idiopathic Thrombocytopenic Purpura
BSC
Non-Small Cell Lung Cancer
Palonosetron
Multiple Myeloma
Gemtuzumab ozogamicin
Acute Myelogenous Leukemia
Open Label (Avatrombopag tablets)
Idiopathic Thrombocytopenic Purpura
Adriamycin
Inflammatory Breast Cancer
Ondansetron
Acute Myelogenous Leukemia
E7080
Solid Tumors
E2027
Lewy Body Disease
ONTAK
Non-Hodgkin's Lymphoma
E6011
Rheumatoid Arthritis
eribulin mesylate + erlotinib
Non-small Cell Lung Cancer
E2086
Narcolepsy
Aricept (donepezil hydrochloride)
Migraine Headache
(+)-SJ000557733 (SJ733)
Malaria, Falciparum
GPI 1485
Parkinson's Disease
Clofarabine
Acute Myeloid Leukemia
Denileukin diftitox
Stage IIIC Melanoma
Lenvatinib + Letrozole
Breast Cancer
Farletuzumab ecteribulin
Solid Tumor
E2006
Chronic Insomnia
Rabeprazole for 90-day period treatment
Postnasal Drainage
E7820 plus cetuximab
Advanced Colorectal Cancer
E7820
Acute Myeloid Leukemia
decitabine (5-aza-2'deoxycytidine)
Chronic Myelogenous Leukemia
GLIADEL
Metastatic Brain Cancer
palonesetron
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Rabeprazole sodium, Tablets (two Tablets)
Healthy
H3B-6545
Breast Neoplasms
E7386
Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Eszopiclone | Phase 3 | Primary Insomnia | - | - |
avatrombopag (lower baseline platelet count) | Phase 3 | Thrombocytopenia Associated With Liver Disease | - | - |
Lorcaserin | Phase 3 | Obesity | - | - |
AQUAVAN® (fospropofol disodium) Injection | Phase 3 | Bronchoscopy | - | - |
Lenvatinib | Phase 3 | Hepatocellular Carcinoma | - | - |
E2007 | Phase 3 | Refractory Partial Seizures | - | - |
Amolimogene | Phase 3 | Uterine Cervical Dysplasia | - | - |
E7337 | Phase 3 | Lesions of the Liver | - | - |
Rabeprazole sodium | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
lemborexant | Phase 3 | Insomnia Disorder | - | - |
Perampanel | Phase 3 | Epilepsy | - | - |
E2007 (perampanel) | Phase 3 | Refractory Partial Seizures | - | - |
fospropofol disodium | Phase 3 | Colonoscopy | - | - |
Rufinamide | Phase 3 | Lennox-Gastaut Syndrome | - | - |
Lecanemab | Phase 3 | Preclinical Alzheimer's Disease | - | - |
E7389 | Phase 3 | Breast Cancer | - | - |
E2020 | Phase 3 | Alzheimer's Type Dementia | - | - |
LEM | Phase 3 | Insomnia | - | - |
Eribulin | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
Rufinamide (E2080) | Phase 3 | Lennox-Gastaut Syndrome | - | - |
Ranirestat | Phase 3 | Mild to Moderate Diabetic Sensorimotor Polyneuropathy | - | - |
eritoran tetrasodium | Phase 3 | Severe Sepsis | - | - |
E2814 | Phase 3 | Alzheimer Disease | - | - |
Avatrombopag | Phase 3 | Chronic Thrombocytopenia | - | - |
Eribulin mesylate intravenous | Phase 3 | Soft Tissue Sarcoma | - | - |
Cinitapride | Phase 3 | Dyspepsia | - | - |
Eperisone | Phase 3 | Muscle Spasm; Back Pain | - | - |
Rabeprazole | Phase 3 | Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin | - | - |
bexarotene with carboplatin and paclitaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
E0302 (mecobalamin) | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
Midazolam HCI | Phase 3 | Conscious Sedation | - | - |
Aricept (donepezil IR) | Phase 3 | Alzheimer's Disease | - | - |
Prior Donzepezil | Phase 3 | Parkinson's Disease | - | - |
Zolpidem tartrate | Phase 3 | Insomnia | - | - |
Rabeprazole ER | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
Sibutramine Hydrochloride Monohydrate | Phase 3 | Obesity | - | - |
E3810 | Phase 3 | Non-erosive Gastroesophageal Reflux Disease | - | - |
Lamotrigine | Phase 3 | Epilepsy | - | - |
Carbamazepine | Phase 3 | Epilepsy | - | - |
bexarotene | Phase 3 | Non-small Cell Lung Cancer | - | - |
Midazolam HCl | Phase 3 | Colonoscopy | - | - |
avatrombopag (higher baseline platelet count) | Phase 3 | Thrombocytopenia Associated With Liver Disease | - | - |
Cytarabine or Supportive Care | Phase 3 | Acute Myeloid Leukemia | - | - |
Irofulven | Phase 3 | Prostate Cancer | - | - |
Aricept | Phase 3 | Cognitive Impairment | - | - |
Eribulin Mesylate | Phase 3 | Breast Cancer | - | - |
Belzutifan | Phase 3 | Carcinoma, Renal Cell | - | - |
Gantenerumab | Phase 3 | Alzheimers Disease | - | - |
phylloquinone (K1) | Phase 3 | Osteoporosis | - | - |
Doxorubicin | Phase 3 | Breast Cancer | - | - |
Aricept (donepezil SR) | Phase 3 | Alzheimer's Disease | - | - |
Oxaliplatin | Phase 3 | Liver Cancer | - | - |
everolimus | Phase 3 | Renal Cell Carcinoma | - | - |
Carboplatin | Phase 3 | Endometrial Neoplasms | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma (HCC) | - | - |
Docetaxel | Phase 3 | Squamous Cell Carcinoma of Head and Neck | - | - |
Decitabine | Phase 3 | Acute Myeloid Leukemia | - | - |
Donepezil hydrochloride | Phase 3 | Attention Impairment | - | - |
Open-labelAdalimumabRescue | Phase 3 | Rheumatoid Arthritis | - | - |
alfacalcidol | Phase 3 | Postmenopausal Osteoporosis | - | - |
Any other approved Antiepileptic Drug | Phase 3 | Lennox-Gastaut Syndrome | - | - |
Open-label Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
Eszopiclone - Non-elderly | Phase 3 | Insomnia | - | - |
Zonegran | Phase 3 | Binge Eating Disorder Associated With Obesity | - | - |
Donepezil | Phase 3 | Alzheimer's Disease | - | - |
Ranitidine | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
Donepezil HCl | Phase 3 | Down Syndrome | - | - |
Prior Donepezil | Phase 3 | Parkinson's Disease | - | - |
Pembrolizumab/Quavonlimab | Phase 3 | Carcinoma, Renal Cell | - | - |
Leucovorin (or Levoleucovorin) | Phase 3 | Advanced/Metastatic Gastroesophageal Adenocarcinoma | - | - |
menatetranone (MK4) | Phase 3 | Osteoporosis | - | - |
H. pylori treatment | Phase 3 | Iron Deficiency Anemia | - | - |
Teprenone | Phase 3 | Gastric or Duodenal Ulcers Caused by Low-dose Aspirin | - | - |
T-614 | Phase 3 | Rheumatoid Arthritis | - | - |
Eszopiclone - Elderly | Phase 3 | Insomnia | - | - |
Eperisone hydrochloride and Diclofenac sodium | Phase 3 | Acute Musculoskeletal Spasm Due to Low Back Pain | - | - |
Clevudine | Phase 3 | Chronic Hepatitis B | - | - |
E7777 | Phase 3 | Peripheral T-cell Lymphoma | - | - |
methylcobalamin | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
E7389 (Eribulin Mesylate) | Phase 3 | HER2-Negative Breast Cancer | - | - |
menatetranone | Phase 3 | Postmenopausal Osteoporosis | - | - |
Dotinurad | Phase 3 | Gout | - | - |
Zonisamide | Phase 3 | Epilepsy; Paediatric Partial Onset Seizures | - | - |
E7389-LF | Phase 2 | Solid Neoplasms | - | - |
Valproic acid | Phase 2 | Leukemia | - | - |
Eribulin mesylate (eribulin; E7389) | Phase 2 | Non Small Cell Lung Cancer | - | - |
Estrogen | Phase 2 | Alzheimer Disease | - | - |
E7080 capsule | Phase 2 | Thyroid Cancer | - | - |
Perampanel Tablet | Phase 2 | Pediatric Epileptic Syndrome | - | - |
Palonosetron (PALO) | Phase 2 | Malignant Glioma | - | - |
Avatrombopag tablets | Phase 2 | Chronic Idiopathic Thrombocytopenic Purpura | - | - |
BOTULINUM TOXIN TYPE B | Phase 2 | Cervical Dystonia | - | - |
Idarubicin | Phase 2 | Leukemia | - | - |
E7090 | Phase 2 | Cholangiocarcinoma | - | - |
AQUAVAN (fospropofol disodium; GPI 15715) | Phase 2 | Postoperative Sedation | - | - |
Decitabine, Arsenic Trioxide and Ascorbic Acid | Phase 2 | Myelodysplastic Syndrome | - | - |
Tazemetostat | Phase 2 | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | - | - |
E5564 | Phase 2 | Sepsis | - | - |
E6742 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
E7050 | Phase 2 | Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | - | - |
E2014 (Botulinum toxin type B) | Phase 2 | Spasmodic Torticollis | - | - |
Irsenontrine | Phase 2 | Dementia With Lewy Bodies | - | - |
Calcipotriene | Phase 2 | Psoriasis Vulgaris | - | - |
Lenvatinib Pill | Phase 2 | Hepatocellular Carcinoma | - | - |
E5555 | Phase 2 | Coronary Artery Disease | - | - |
Farletuzumab | Phase 2 | Platinum-Sensitive Ovarian Cancer in First Relapse | - | - |
fospropofol | Phase 2 | Ischemic Coronary Artery Disease | - | - |
E6201 | Phase 2 | Chronic Plaque Psoriasis | - | - |
Irofulven + capecitabine | Phase 2 | Thyroid Cancer | - | - |
BB-1701 | Phase 2 | Breast Cancer | - | - |
E7389 28 Day Cycle | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Perampanel Oral Suspension | Phase 2 | Pediatric Epileptic Syndrome | - | - |
E7449 alone | Phase 2 | Malignant Solid Tumour | - | - |
APD356 | Phase 2 | Obesity | - | - |
ONTAK (denileukin diftitox) | Phase 2 | Lymphoma, B-Cell | - | - |
Pegylated interferon (PEG-IFN) | Phase 2 | Thrombocytopenia | - | - |
Iomeprole | Phase 2 | Lesion | - | - |
CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy | Phase 2 | Peripheral T-Cell Lymphoma | - | - |
E2020-Donepezil hydrochloride | Phase 2 | Down Syndrome | - | - |
Eribulin mesilate | Phase 2 | Refractory or Recurrent Solid Tumors | - | - |
E7070 | Phase 2 | Kidney Neoplasms | - | - |
Ixabepilone | Phase 2 | Breast Cancer | - | - |
MORAb-004 (monoclonal antibody) | Phase 2 | Metastatic Melanoma | - | - |
Lenvatinib (DTC Cohort) | Phase 2 | Thyroid Cancer | - | - |
Blinded (Avatrombopoag tablets) | Phase 2 | Idiopathic Thrombocytopenic Purpura | - | - |
BSC | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Palonosetron | Phase 2 | Multiple Myeloma | - | - |
Gemtuzumab ozogamicin | Phase 2 | Acute Myelogenous Leukemia | - | - |
Open Label (Avatrombopag tablets) | Phase 2 | Idiopathic Thrombocytopenic Purpura | - | - |
Adriamycin | Phase 2 | Inflammatory Breast Cancer | - | - |
Ondansetron | Phase 2 | Acute Myelogenous Leukemia | - | - |
E7080 | Phase 2 | Solid Tumors | - | - |
E2027 | Phase 2 | Lewy Body Disease | - | - |
ONTAK | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
E6011 | Phase 2 | Rheumatoid Arthritis | - | - |
eribulin mesylate + erlotinib | Phase 2 | Non-small Cell Lung Cancer | - | - |
E2086 | Phase 2 | Narcolepsy | - | - |
Aricept (donepezil hydrochloride) | Phase 2 | Migraine Headache | - | - |
(+)-SJ000557733 (SJ733) | Phase 2 | Malaria, Falciparum | - | - |
GPI 1485 | Phase 2 | Parkinson's Disease | - | - |
Clofarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
Denileukin diftitox | Phase 2 | Stage IIIC Melanoma | - | - |
Lenvatinib + Letrozole | Phase 2 | Breast Cancer | - | - |
Farletuzumab ecteribulin | Phase 2 | Solid Tumor | - | - |
E2006 | Phase 2 | Chronic Insomnia | - | - |
Rabeprazole for 90-day period treatment | Phase 2 | Postnasal Drainage | - | - |
E7820 plus cetuximab | Phase 2 | Advanced Colorectal Cancer | - | - |
E7820 | Phase 2 | Acute Myeloid Leukemia | - | - |
decitabine (5-aza-2'deoxycytidine) | Phase 2 | Chronic Myelogenous Leukemia | - | - |
GLIADEL | Phase 2 | Metastatic Brain Cancer | - | - |
palonesetron | Phase 2 | Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC | - | - |
Rabeprazole sodium, Tablets (two Tablets) | Phase 2 | Healthy | - | - |
H3B-6545 | Phase 2 | Breast Neoplasms | - | - |
E7386 | Phase 2 | Melanoma | - | - |
dMMR endometrial cancer
1 drug in this indication
Early Alzheimer's Disease
1 drug in this indication
advanced renal cell carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Eisai's drug pipeline?→
CatalystAlert tracks 154 drug candidates in Eisai's (ESALY) pipeline across Phase 3, Phase 2. Its lead program is Lenvatinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Eisai's next FDA catalyst?→
Eisai's (ESALY) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ESALY biotech catalysts?→
Add ESALY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Eisai's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.